Výsledky vyhledávání - "B. T. Svanes Fevang"

POS1366 RITUXIMAB IN IgG4-RD: AN OPEN-LABEL NON-RANDOMIZED OBSERVATIONAL STUDY

Autor: J. Vikse, Ø. Midtvedt, Ø. Molberg, B. T. Svanes Fevang, Ø. Palm, T. Garen, K. B. Norheim, G. Bakland, M. Wallenius, A. M. Hoffmann-Vold

Publikováno v: Annals of the Rheumatic Diseases. 81:1022-1023

BackgroundIgG4-related disease (IgG4-RD) is a rare, heterogenous and potentially severe disease. An open-label trial demonstrated efficacy of rituximab (RTX) in IgG4-RD [1]. Recently, four distinct phenotypes of IgG4-RD were identified [2]. There is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45ade5fbff30a933d5d14d5acfd13814
https://doi.org/10.1136/annrheumdis-2022-eular.4340

Zobrazit plný text záznamu

OP0277 PERSISTENT EXCESS OF STROKE EVENTS IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT STUDY FROM HORDALAND, NORWAY FROM 1972 TO 2014

Autor: C. L. Alsing, J. Igland, G. S. Tell, H. Næss, T. W. Nystad, B. T. Svanes Fevang

Publikováno v: Annals of the Rheumatic Diseases. 81:184.2-184

BackgroundPatients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease (CVD), including stroke [1]. After the introduction of biological DMARDs in 1999 and the treat to target strategy, more patients reach low disease activit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::58d44e6811f265ed12503950fed60b94
https://doi.org/10.1136/annrheumdis-2022-eular.919

Zobrazit plný text záznamu

POS0580 TRENDS IN THE OCCURRENCE OF ISCHEMIC HEART DISEASE OVER TIME IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT STUDY FROM NORWAY OF 1821 PATIENTS FROM 1972 TO 2014

Autor: C. L. Alsing, T. W. Nystad, J. Igland, C. G. Gjesdal, H. Midtbø, G. S. Tell, B. T. Svanes Fevang

Publikováno v: Annals of the Rheumatic Diseases. 81:557.1-557

BackgroundPrevious studies have shown that rheumatoid arthritis is associated with a 1.5 to 2.0 times increased risk of acute myocardial infarction (AMI) and ischemic heart disease (IHD) compared with the general population [1,2]. RA treatment has im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7f1ec7f544499fae27c2b0f9ed82f1b
https://doi.org/10.1136/annrheumdis-2022-eular.111

Zobrazit plný text záznamu

POS0215 PHENOTYPES AND DISEASE CHARACTERISTICS OF IgG4-RELATED DISEASE IN NORWAY

Autor: J. Vikse, Ø. Midtvedt, Ø. Molberg, B. T. Svanes Fevang, Ø. Palm, T. Garen, K. B. Norheim, G. Bakland, M. Wallenius, A. M. Hoffmann-Vold

Publikováno v: Annals of the Rheumatic Diseases. 81:343.1-344

BackgroundMilestones in the field of IgG4-related disease (IgG4-RD) include the 2011 Comprehensive Diagnostic Criteria (CDC) (1), the 2019 ACR/EULAR classification criteria (2), and the recent identification of four distinct clinical phenotypes (3).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7abdcfc1d7f3cea1ae1c5bc4a8660a81
https://doi.org/10.1136/annrheumdis-2022-eular.1466

Zobrazit plný text záznamu

POS0339 PREDICTORS OF DEATH IN PATIENTS DIAGNOSED WITH GIANT CELL ARTERITIS IN WESTERN NORWAY 1972-2012

Autor: B. T. Svanes Fevang, Jörg Assmus, Lene Kristin Brekke

Publikováno v: Annals of the Rheumatic Diseases. 80:397.2-398

Background:Giant cell arteritis (GCA) is the most common systemic vasculitis in adults, and the number of incident cases worldwide is projected to increase [1]. Evidence as to whether or not GCA confers a mortality risk is conflicting, and many studi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c0bd89ad3590183e3c71b8f823627a3
https://doi.org/10.1136/annrheumdis-2021-eular.1988

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání